FDA OKs First Recombinant von Willebrand Factor (Vonvendi)FDA OKs First Recombinant von Willebrand Factor (Vonvendi)

The approval of Vonvendi provided an additional therapeutic option for the treatment of bleeding episodes in patients with von Willebrand disease, according to the FDA. FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news